Literature DB >> 26492839

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.

Alexander V Louie1, Erik van Werkhoven2, Hanbo Chen3, Egbert F Smit4, Marinus A Paul5, Joachim Widder6, Harry J M Groen7, Ben E E M van den Borne8, Katrien De Jaeger9, Ben J Slotman10, Suresh Senan10.   

Abstract

We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy or SBRT) versus surgical resection for medically operable stage IA non-small cell lung cancer. ROSEL closed prematurely after accruing and randomizing 22 patients. This exploratory analysis found the global health related quality of life and indirect costs to be significantly favorable and cheaper, with SABR.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Lung cancer; Patient reported outcomes; Quality of life; SABR; SBRT; Surgery

Mesh：

Year:  2015        PMID： 26492839     DOI： 10.1016/j.radonc.2015.08.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  26 in total

1.  SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation.

Authors:  Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Surgery versus SABR for early stage non-small cell lung cancer: the moving target of equipoise.

Authors:  Houda Bahig; Hanbo Chen; Alexander V Louie
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

4.  Patient-clinician communication among patients with stage I lung cancer.

Authors:  Shannon M Nugent; Sara E Golden; Charles R Thomas; Mark E Deffebach; Mithran S Sukumar; Paul H Schipper; Brandon H Tieu; Drew Moghanaki; Juan Wisnivesky; Christopher Slatore
Journal:  Support Care Cancer       Date:  2017-12-05       Impact factor: 3.603

5.  Shared decision making in the treatment of stage I non small cell lung cancer-a choice which should equally involve both sides.

Authors:  Aurel Ottlakan; Jozsef Furak; Gaetano Rocco
Journal:  Ann Transl Med       Date:  2017-09

6.  Patients reported outcomes in thoracic surgery.

Authors:  Cecilia Pompili; Kate Absolom; Galina Velikova; Leah Backhus
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 7.  Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.

Authors:  Tejan P Diwanji; Pranshu Mohindra; Melissa Vyfhuis; James W Snider; Chaitanya Kalavagunta; Sina Mossahebi; Jen Yu; Steven Feigenberg; Shahed N Badiyan
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 8.  SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?

Authors:  Hanbo Chen; Alexander V Louie
Journal:  Curr Treat Options Oncol       Date:  2016-06

9.  Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes.

Authors:  Duc Ha; Andrew L Ries; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2020-01-21       Impact factor: 3.603

10.  Survival of Primary Stereotactic Body Radiation Therapy Compared With Surgery for Operable Stage I/II Non-small Cell Lung Cancer.

Authors:  Rhami Khorfan; Timothy J Kruser; Julia M Coughlin; Ankit Bharat; Karl Y Bilimoria; David D Odell
Journal:  Ann Thorac Surg       Date:  2020-03-05       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.